Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
相关临床试验
29
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
进行中（未招募）
10
34.5%
已完成
9
31.0%
尚未招募
1
3.5%
招募中
3
10.3%
终止
3
10.3%
Unknown
3
10.3%
暂无批准数据
- A new market report forecasts continued expansion of the global CD70-targeting therapies pipeline across the United States, China, and Europe as candidates advance through clinical trials and regulatory review. - Clinical development increasingly incorporates combination regimens pairing CD70 therapies with immunotherapies, epigenetic inhibitors, chemotherapy, and targeted agents to strengthen responses and address resistance. - Leading companies including Allogene Therapeutics, Ambrx (Johnson & Johnson), Molecular Partners, and CRISPR Therapeutics are advancing differentiated programs through proprietary platforms such as allogeneic cell therapy and DARPin engineering. - The report highlights biomarker-driven development and patient-selection strategies as key levers for more precise clinical positioning across leukemia, lymphoma, renal cell carcinoma, and autoimmune indications.
- Orano Med is advancing a pipeline of lead-212-based targeted alpha therapies, with its lead asset AlphaMedix showing positive phase 2 results in neuroendocrine tumors in collaboration with Sanofi and RadioMedix. - The company holds a unique competitive advantage through parent company Orano's ownership of what may be the world's largest stock of pure thorium, enabling unlimited access to the rare lead-212 isotope. - Orano Med has built a complete value chain spanning isotope extraction, drug manufacturing, and R&D, with recent expansions including new headquarters in France and an industrial-scale production facility. - Big Pharma interest in targeted alpha therapies is intensifying, with AstraZeneca and Bristol Myers Squibb making significant investments in actinium-225-based platforms, while Orano Med also partners with Roche on a metastatic colorectal cancer program.
- The first tetraspecific antibody approval is expected by 2029, marking a significant milestone in multispecific immunotherapy development. - Sichuan Baili Pharmaceutical's Emfizatamab is currently in Phase II trials for hematological malignancies, representing a leading candidate in the field. - The bispecific antibody market has already exceeded $10 billion, with tetraspecific antibodies expected to capture even greater market share due to their enhanced targeting capabilities. - China and the USA are dominating the tetraspecific antibody clinical development landscape, with multiple companies advancing candidates through trials.
- Molecular Partners has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer effective October 1, 2025, bringing extensive oncology drug development experience from senior roles at Roche, MorphoSys, Boehringer Ingelberg, and SOTIO Biotech. - Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. - The appointment strengthens Molecular Partners' leadership team as the clinical-stage biotech company continues developing its proprietary DARPin platform for medical challenges that other drug modalities cannot readily address. - Steegmaier previously served as CSO at SOTIO Biotech and Head of Research at MorphoSys, with particular expertise in antibody-based therapeutics in immuno-oncology and hematology-oncology.
- Molecular Partners' tetraspecific T-cell engager MP0533 achieved over 30% response rate in relapsed/refractory AML patients using an accelerated dosing regimen in cohort 8. - One patient maintained a complete response beyond 6 months, demonstrating potential for durable clinical benefit with the optimized treatment protocol. - The company is advancing to cohort 9 with further dosing improvements and plans combination studies with azacitidine/venetoclax based on encouraging antitumor activity. - Data presented at EHA 2025 support continued dose optimization to maximize therapeutic exposure and clinical responses in this difficult-to-treat patient population.
- Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company. - Dr. Vasconcelles will oversee the company's research, development, and medical affairs infrastructure while supporting OJEMDA's growth and expanding the pipeline of targeted therapies. - The appointment comes at a pivotal time for Day One as it transitions from focusing primarily on pediatric cancer to developing transformative medicines for patients of all ages with life-threatening diseases. - Dr. Vasconcelles previously served as Executive Vice President at ImmunoGen, where he led the transformation into a global biotech enterprise and optimized ELAHERE's commercialization strategy.
- Molecular Partners' Radio-DARPin MP0712, targeting DLL3, is set to begin first-in-human trials in 2025, marking a key advancement in targeted cancer therapy. - The collaboration between Molecular Partners and Orano Med expands to ten Radio-DARPin programs, enhancing their pipeline of targeted alpha therapies. - Clinical data for MP0533 in relapsed/refractory AML shows improved response rates with intensified dosing, with further updates expected in 2025.
- Molecular Partners' MP0533 phase 1/2a study shows an acceptable safety profile and initial antileukemic activity in relapsed/refractory AML patients. - A clinical protocol amendment is underway to optimize MP0533 dosing, aiming to enhance drug exposure and maximize its therapeutic potential. - Preclinical data for MP0621, a Switch-DARPin, demonstrates its mechanism in vivo, effectively killing cKit+ cells while reducing off-target effects. - MP0621 is being evaluated for potential partnering opportunities, aligning with Molecular Partners' focus on oncology therapeutics.
